Improving Surgical Outcomes

Deltex Medical Group PLC
05 July 2007


                            Deltex Medical Group plc

 Independent report highlights CardioQ's role in improving surgical care in the
                                      NHS


5 July 2007 - Deltex Medical Group plc ('Deltex Medical' or 'Company'), the UK's
leading haemodynamic monitoring company, announces the publication today by the
Improving Surgical Outcomes Group (ISOG) of a pamphlet entitled 'Modernising
Care for Patients Undergoing Major Surgery: Implementation Guide'.

The report highlights three key areas for improved outcomes: objective
pre-operative assessment of patient fitness, intra-operative fluid intervention
and appropriate levels of post-operative critical care for higher risk patients.
In respect of fluid management during surgery, the report's executive summary
states:

'Accurate fluid intervention, through the use of monitors measuring blood flow
during surgery, reduces by more than half both the number and severity of
post-operative complications. Patients on average leave hospital three days
sooner, reducing average lengths of stay by 20%.'

Four of the eight case studies in the report, from NHS hospitals in Gillingham,
Worthing, Newcastle and Paisley, highlight the benefits of using the CardioQTM
for accurate fluid intervention during surgery. A fifth case study is from
University College London Hospital (UCLH), which in March this year UCLH
announced that it was implementing the CardioQ as a standard of care for almost
all higher risk surgical patients: the CardioQ has been a standard of care in
UCLH's intensive care unit for more than 10 years.

ISOG is an independent group of UK surgeons, anaesthetists and intensive care
specialists. In 2005 ISOG published a document, 'Modernising Care for Patients
Undergoing Major Surgery: Improving Patient Outcomes and Increasing Clinical
Efficiency' setting out the evidence base supporting the clinical and economic
cases for improving NHS standard care before, during and after surgery. Both
ISOG reports are available to download at www.reducinglengthofstay.org/isog.html


Deltex Medical's Chief Executive, Andy Hill commented:

'This report by an independent leading group of clinicians increases further the
pressure on the NHS to implement the CardioQ as a standard of care during
surgery. ISOG have stated clearly the benefits of being able to measure blood
flow accurately during surgery: reducing post-operative complications by more
than half and reducing patients' lengths of stay by three days.

'Oesophageal Doppler monitoring is the only haemodynamic monitoring technology
which directly measures blood flows and is also the only technology to detect
changes in blood flows either rapidly or accurately. Deltex Medical is the world
leader in oesophageal Doppler monitoring.'


For further information, please contact:-

Deltex Medical Group plc             01243 774 837
Nigel Keen, Chairman                 [e-mail]
Andy Hill, Chief Executive           [e-mail]
Ewan Phillips, Finance Director      [e-mail]

Gavin Anderson & Company             020 7554 1400
Deborah Walter                       [e-mail]
Robert Speed                         [e-mail]

Charles Stanley Securities           020 7149 6457
Philip Davies                        [e-mail]
Russell Cook                         [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange